• Adult Immunization
  • Hepatology
  • Pediatric Immunization
  • Screening
  • Psychiatry
  • Allergy
  • Women's Health
  • Cardiology
  • Pediatrics
  • Dermatology
  • Endocrinology
  • Pain Management
  • Gastroenterology
  • Geriatrics
  • Infectious Disease
  • Obesity Medicine
  • Rheumatology
  • Oncology
  • Nephrology
  • Neurology
  • Pulmonology

CV Risk Stratification Decision Factors

News
Video

Cardiologist Deepak Bhatt, MD, discusses factors to consider when assessing the need for cardiovascular risk management or reduction.

A discussion on which factors to consider when assessing the need for management/reduction of cardiovascular risk.

Related Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Where Should SGLT-2 Inhibitor Therapy Begin? Thoughts from Drs Mikhail Kosiborod and Neil Skolnik
Related Content
ACC 2025: Cardiovascular Benefits of Semaglutide 2.4 mg Highlighted in Real-World Study

ACC 2025: Cardiovascular Benefits of Semaglutide 2.4 mg Highlighted in Real-World Study

Sydney Jennings
April 1st 2025
Article

Semaglutide 2.4 mg significantly lowered the risk of MACE and mortality in patients with ASCVD and overweight or obesity but without diabetes, researchers reported.

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

Sydney Jennings
August 30th 2023
Podcast

Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.

Oral Semaglutide Lowers Risk of MACE 14% in Adults with T2D, ASCVD and/or CKD: Final Phase 3 SOUL Trial Readout/ image credit American College of Cardiology

Oral Semaglutide Lowers Risk of MACE 14% in High-Risk Adults: Final Phase 3 SOUL Trial Readout

Grace Halsey
March 31st 2025
Article

ACC.25. The results seen with the only oral GLP-1 mimetic reflect "a profound clinical impact" for adults at high risk for MACE who are averse to injectable therapy.

Primary Viewpoints Episode 4: Lp(a): The Next CVD Target?

Primary Viewpoints Episode 4: Lp(a): The Next CVD Target?

Patient Care Editorial Staff
October 29th 2020
Podcast

Patrick Moriarty, MD, from the University of Kansas Medical Center, discusses the role of Lp(a) as a risk factor for cardiovascular disease and the phase 3 trials of a potential treatment.

Better CV Health Tied to Lower Neurodegeneration Risk: Daily Dose / image credit: ©New Africa/AdobeStock

Better CV Health Tied to Lower Neurodegeneration Risk: Daily Dose

Sydney Jennings
March 27th 2025
Article

Your daily dose of the clinical news you may have missed.

Long COVID's Long Road: A Year-5 Update with Noah Greenspan DPT, PT, CCS, EMT-B

Long COVID's Long Road: A Year 5 Update with Noah Greenspan DPT, PT, CCS, EMT-B

Infection Control Today® Editorial Staff
March 26th 2025
Article

Five years after the COVID-19 pandemic was declared, the protean syndrome dubbed long COVID continues to affect millions; Greenspan is dedicated to helping.

© 2025 MJH Life Sciences

All rights reserved.